Q2 Earnings Estimate for KYMR Issued By B. Riley

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Investment analysts at B. Riley issued their Q2 2025 earnings estimates for shares of Kymera Therapeutics in a research note issued to investors on Wednesday, July 30th. B. Riley analyst M. Mamtani anticipates that the company will post earnings per share of ($1.01) for the quarter. B. Riley currently has a “Strong-Buy” rating and a $60.00 target price on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.71) EPS, FY2026 earnings at ($4.03) EPS, FY2027 earnings at ($4.56) EPS and FY2028 earnings at ($3.80) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.10. The business had revenue of $22.10 million during the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The business’s revenue for the quarter was up 114.6% on a year-over-year basis. During the same period last year, the business posted ($0.69) earnings per share.

KYMR has been the topic of several other research reports. Wells Fargo & Company lowered their price target on shares of Kymera Therapeutics from $57.00 to $53.00 and set an “overweight” rating on the stock in a research report on Thursday, June 26th. Stifel Nicolaus started coverage on Kymera Therapeutics in a research report on Tuesday, May 20th. They issued a “buy” rating and a $55.00 price target for the company. Guggenheim reissued a “buy” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, June 3rd. Jefferies Financial Group set a $64.00 target price on Kymera Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 25th. Finally, Oppenheimer reiterated an “outperform” rating and set a $53.00 price target (down from $56.00) on shares of Kymera Therapeutics in a research report on Friday, June 27th. Two analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $59.11.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock opened at $42.96 on Friday. The stock has a market capitalization of $2.80 billion, a P/E ratio of -13.86 and a beta of 2.18. Kymera Therapeutics has a 52-week low of $19.44 and a 52-week high of $53.27. The stock’s 50-day simple moving average is $43.85 and its 200 day simple moving average is $36.57.

Institutional Trading of Kymera Therapeutics

Hedge funds have recently bought and sold shares of the company. KBC Group NV raised its stake in shares of Kymera Therapeutics by 15.2% during the first quarter. KBC Group NV now owns 2,479 shares of the company’s stock worth $68,000 after acquiring an additional 328 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Kymera Therapeutics by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company’s stock valued at $110,000 after purchasing an additional 343 shares during the last quarter. Summit Investment Advisors Inc. raised its position in Kymera Therapeutics by 9.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock worth $198,000 after purchasing an additional 406 shares during the period. Farther Finance Advisors LLC raised its position in Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after purchasing an additional 540 shares during the period. Finally, Comerica Bank boosted its position in Kymera Therapeutics by 3.6% during the first quarter. Comerica Bank now owns 21,374 shares of the company’s stock valued at $585,000 after buying an additional 743 shares during the period.

Insider Activity at Kymera Therapeutics

In other news, Director Bvf Partners L. P/Il acquired 317,167 shares of the business’s stock in a transaction dated Monday, June 30th. The stock was purchased at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the acquisition, the director owned 2,798,795 shares of the company’s stock, valued at $123,146,980. This trade represents a 12.78% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Elena Ridloff sold 12,000 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total value of $553,200.00. The disclosure for this sale can be found here. Insiders sold a total of 48,349 shares of company stock worth $2,334,301 in the last three months. 16.01% of the stock is owned by insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.